» Articles » PMID: 27544822

The St. Gallen Surrogate Classification for Breast Cancer Subtypes Successfully Predicts Tumor Presenting Features, Nodal Involvement, Recurrence Patterns and Disease Free Survival

Overview
Journal Breast
Publisher Elsevier
Specialties Endocrinology
Oncology
Date 2016 Aug 22
PMID 27544822
Citations 59
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: To evaluate how the St. Gallen intrinsic subtype classification for breast cancer surrogates predicts disease features, recurrence patterns and disease free survival.

Materials And Methods: Subtypes were classified by immunohistochemical staining according to St. Gallen subtypes classification in a 5-tyre system: luminal A, luminal B HER2-neu negative, luminal B HER2-neu positive, HER2-neu non luminal or basal-like. Data were obtained from the records of patients with invasive breast cancer treated at our institution. Recurrence data and site of first recurrence were recorded. The chi(2) test, analysis of variance, and multivariate logistic regression analysis were used to determine associations between surrogates and clinicopathologic variables.

Results: A total of 2.984 tumors were classifiable into surrogate subtypes. Significant differences in age, tumor size, nodal involvement, nuclear grade, multicentric/multifocal disease (MF/MC), lymphovascular invasion, and extensive intraductal component (EIC) were observed among surrogates (p < 0.0001). After adjusting for confounding factors surrogates remained predictive of nodal involvement (luminal B HER2-neu pos. OR = 1.49 p = 0.009, non-luminal HER2-neu pos. OR = 1.61 p = 0.015 and basal-like OR = 0.60, p = 0.002) while HER2-neu positivity remained predictive of EIC (OR = 3.10, p < 0.0001) and MF/MC (OR = 1.45, p = 0.02). Recurrence rates differed among the surrogates and were time-dependent (p = 0.001) and site-specific (p < 0.0001).

Conclusion: The St. Gallen 5-tyre surrogate classification for breast cancer subtypes accurately predicts breast cancer presenting features (with emphasis on prediction of nodal involvement), recurrence patterns and disease free survival.

Citing Articles

Long-term outcomes of Türkiye's first population-based mammography screening program: a decade of breast cancer detection and survival analysis in Bahçeşehir.

Ozcinar B, Aribal E, Cabioglu N, Gurdal S, Varol G, Akyurt N BMC Womens Health. 2025; 25(1):5.

PMID: 39755627 PMC: 11700443. DOI: 10.1186/s12905-024-03521-1.


Predictive factors for complete pathologic response in luminal breast cancer: impact of ki67 and HER2 low expression.

Miras I, Gil A, Benavent M, Castilla M, Vieites B, Dominguez-Cejudo M Ther Adv Med Oncol. 2024; 16:17588359241309169.

PMID: 39734711 PMC: 11672595. DOI: 10.1177/17588359241309169.


Roles of miR-20a-5p in breast cancer based on the clinical and multi-omic (CAMO) cohort and in vitro studies.

Tylden E, Delgado A, Lukic M, Moi L, Rasmussen Busund L, Pedersen M Sci Rep. 2024; 14(1):25022.

PMID: 39443510 PMC: 11499649. DOI: 10.1038/s41598-024-75557-0.


Comprehensive diagnosis of advanced-stage breast cancer: exploring detection methods, molecular subtypes, and demographic influences - A cross-sectional study.

Silva Rivas F, Goncalves R, Mota B, Sorpreso I, Toporcov T, Filassi J Clinics (Sao Paulo). 2024; 79:100510.

PMID: 39413498 PMC: 11530810. DOI: 10.1016/j.clinsp.2024.100510.


Mast cell heparanase promotes breast cancer stem-like features via MUC1/estrogen receptor axis.

Bongiorno R, Lecchi M, Botti L, Bosco O, Ratti C, Fontanella E Cell Death Dis. 2024; 15(9):709.

PMID: 39349458 PMC: 11442964. DOI: 10.1038/s41419-024-07092-9.